New drug cocktail aims to tame deadly brain tumors

NCT ID NCT02331498

Ongoing Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the targeted drug pazopanib to standard chemotherapy (temozolomide) can safely control glioblastoma, an aggressive brain cancer. About 51 adults who had surgery and chemoradiation will receive the combination. The main goal is to find the best dose with acceptable side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pazopanib (a targeted cancer drug) combined with temozolomide (chemotherapy)
What this could lead to: If successful, this could lead to a new combination treatment that helps control glioblastoma for longer after standard therapy.
What could go wrong: This is an early-phase trial with only 51 participants, so results may not apply widely. The drug combination may cause significant side effects like high blood pressure or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, Cedex 2, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.